Insider Selling: Gilead Sciences, Inc. (NASDAQ:GILD) Director Sells 5,000 Shares of Stock

Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) Director Jeffrey Bluestone sold 5,000 shares of the company's stock in a transaction on Monday, July 14th. The stock was sold at an average price of $109.74, for a total transaction of $548,700.00. Following the transaction, the director owned 8,920 shares in the company, valued at approximately $978,880.80. The trade was a 35.92% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Gilead Sciences Stock Performance

GILD traded up $0.79 during trading on Wednesday, hitting $109.85. 3,957,440 shares of the company traded hands, compared to its average volume of 7,682,451. The firm has a market cap of $136.65 billion, a P/E ratio of 23.13, a price-to-earnings-growth ratio of 0.71 and a beta of 0.29. Gilead Sciences, Inc. has a one year low of $70.78 and a one year high of $119.96. The company has a quick ratio of 1.23, a current ratio of 1.37 and a debt-to-equity ratio of 1.16. The stock's fifty day moving average is $108.37 and its 200 day moving average is $104.94.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating the consensus estimate of $1.77 by $0.04. The business had revenue of $6.67 billion for the quarter, compared to the consensus estimate of $6.77 billion. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The company's revenue was down .3% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.32) earnings per share. As a group, equities analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 27th. Shareholders of record on Friday, June 13th were issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.88%. The ex-dividend date of this dividend was Friday, June 13th. Gilead Sciences's dividend payout ratio (DPR) is presently 66.53%.

Institutional Investors Weigh In On Gilead Sciences

Several institutional investors have recently added to or reduced their stakes in the business. Southland Equity Partners LLC lifted its holdings in Gilead Sciences by 2.9% during the second quarter. Southland Equity Partners LLC now owns 3,285 shares of the biopharmaceutical company's stock valued at $364,000 after purchasing an additional 92 shares during the last quarter. Redwood Financial Network Corp lifted its holdings in shares of Gilead Sciences by 4.0% in the fourth quarter. Redwood Financial Network Corp now owns 2,530 shares of the biopharmaceutical company's stock worth $234,000 after buying an additional 98 shares in the last quarter. Twelve Points Wealth Management LLC lifted its holdings in shares of Gilead Sciences by 1.5% in the second quarter. Twelve Points Wealth Management LLC now owns 6,499 shares of the biopharmaceutical company's stock worth $721,000 after buying an additional 98 shares in the last quarter. Argentarii LLC lifted its holdings in shares of Gilead Sciences by 3.0% in the first quarter. Argentarii LLC now owns 3,392 shares of the biopharmaceutical company's stock worth $380,000 after buying an additional 99 shares in the last quarter. Finally, Nicolet Advisory Services LLC lifted its holdings in shares of Gilead Sciences by 2.9% in the fourth quarter. Nicolet Advisory Services LLC now owns 3,580 shares of the biopharmaceutical company's stock worth $322,000 after buying an additional 100 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have recently issued reports on GILD. JPMorgan Chase & Co. upped their target price on shares of Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research note on Thursday, March 27th. Morgan Stanley upped their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research note on Friday, April 25th. Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. Oppenheimer reduced their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research note on Friday, April 25th. Finally, Cantor Fitzgerald began coverage on shares of Gilead Sciences in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 target price for the company. Nine analysts have rated the stock with a hold rating, fourteen have given a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $111.38.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.